Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer

References

• Tolley DA, Hargreave TB, Smith PH, et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed). 1988;296(6639):1759–1761.
   PubMedGoogle Scholar
• Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer. Eur Urol. 2002;41:105–112.
   PubMed Web of Science ®Google Scholar
• Oosterlinck W, Sylvester R, Babjuk M, et al. Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? Eur Urol. 2011;59:374–376.
   PubMed Web of Science ®Google Scholar
• Berrum-Svennung I, Granfors T, Jahnson S, et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol. 2008;179:101–105.
   PubMed Web of Science ®Google Scholar
• Gudjonsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009;55:773–780.
   PubMed Web of Science ®Google Scholar
• Cookson MS, Chang SS, Oefelein MG, et al. National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol. 2012;187:1571–1576.
   PubMed Web of Science ®Google Scholar
• Palou-Redorta J, Roupret M, Gallagher JR, et al. The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries. World J Urol. 2014;32:525–530.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016;69:231–244.
   PubMed Web of Science ®Google Scholar
• Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, et al. Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol. 2017;73:226–232.
   PubMed Web of Science ®Google Scholar
• Karsh L, Shore N, Satzsteen D. Integrated results of two multicenter, randomised, placebo controlled, double blind, phase 3 trials (SPI-611/612) of single dose intravesical apaziquone immediately following resection in patients with nonmuscle invasive bladder cancer. J Urol. 2016;95(supplement):Abstracte290.
   Google Scholar
• Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12:871–879.
   PubMed Web of Science ®Google Scholar
• Abern MR, Owusu RA, Anderson MR, et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw. 2013;11:477–484.
   PubMed Web of Science ®Google Scholar
• Perlis N, Zlotta AR, Beyene J, et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol. 2013;64:421–430.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186–2190.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53:709–719.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–475.
   PubMed Web of Science ®Google Scholar
• Onishi T, Sasaki T, Hoshina A, et al. Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor. Anticancer Res. 2011;31:1471–1474.
   PubMed Web of Science ®Google Scholar
• Whelan P, Griffiths G, Stower M, et al. Preliminary results of a MRC randomised trial of post-operative irrigation of superficial bladder cancer. Proc Am Soc Clin Oncol. 2001;20:abstract 708.
   Google Scholar
• Decaestecker K, Lumen N, Ringoir A, et al. Ablative intravesical chemotherapy for small recurrent non-muscle-invasive bladder cancer: a prospective study. Urol Int. 2016;96:14–19.
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Rintala E, Hellstrom P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol. 2002;42:167–174.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Witjes WP, Idema JG, et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol. 2008;53:984–991.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuijzen JA, Bex A, Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol. 2003;43:711–712.
   PubMed Web of Science ®Google Scholar
• Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol. 2004;46:336–338.
   PubMed Web of Science ®Google Scholar
• Elmamoun MH, Christmas TJ, Woodhouse CR. Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)–avoidance, recognition, management and consent. BJU Int. 2014;113:E34–8.
   PubMed Web of Science ®Google Scholar
• Burks FN, Liu AB, Suh RS, et al. Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. J Urol. 2012;188:2108–2113.
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol. 2007;178:1201–1205.
   PubMed Web of Science ®Google Scholar
• Al Hussein Al Awamlh B, Lee R, Chughtai B, et al. A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration. Urology. 2015;85:381–386.
   PubMed Web of Science ®Google Scholar
• Hernandez V, Llorente C, de la Pena E, et al. Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. Urol Oncol. 2016;34:165, e19–e23.
   Web of Science ®Google Scholar
• Hurle R, Lazzeri M, Vanni E, et al. Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project. J Urol. 2017;199:401–406.
   PubMed Web of Science ®Google Scholar
• Kassouf W, Traboulsi SL, Kulkarni GS, et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J. 2015;9:E690–704.
   PubMed Web of Science ®Google Scholar
• Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer. 2016;2:27–36.
   PubMedGoogle Scholar
• Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178:2314–2330.
   PubMed Web of Science ®Google Scholar
• Rao PK, Stephen Jones J. Routine perioperative chemotherapy instillation with initial bladder tumor resection: a reconsideration of economic benefits. Cancer. 2009;115:997–1004.
   PubMed Web of Science ®Google Scholar
• Lee CT, Barocas D, Globe DR, et al. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J Urol. 2012;188:2114–2119.
   PubMed Web of Science ®Google Scholar
• Bohle A, Leyh H, Frei C, et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol. 2009;56:495–503.
   PubMed Web of Science ®Google Scholar
• Phillips RM, Hendriks HR, Sweeney JB, et al. Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. Expert Opin Drug Metab Toxicol. 2017;13:783–791.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, van der Heijden AG, Cornel EB, et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol. 2009;27:337–342.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Karsh L, Soloway M, et al. Improved efficacy of adjuvant, single dose intravesical apaziquone by timing post-resection in two double blind, randomised, placebo-controlled phase 3 studies in non-muscle invasive bladder cancer. J Urol. 2016; 195(supplement):abstracte136.
   Google Scholar
• Bai Y, Liu L, Yuan H, et al. Safety and efficacy of transurethral laser therapy for bladder cancer: a systematic review and meta-analysis. World J Surg Oncol. 2014;12:301.
   PubMed Web of Science ®Google Scholar
• Colombo R, Rocchini L, Suardi N, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol. 2012;62:797–802.
   PubMed Web of Science ®Google Scholar